Ouye Deep Plus

Ouye Deep Plus: High-Density HA Volumizer for Profound Deficit Correction & Structural Support

Ouye Deep Plus , manufactured by **Medytox Inc.** (South Korea), is a **high-density, high-G prime, monophasic hyaluronic acid (HA) dermal filler** designed for **deep volumetric restoration and structural contouring** in areas requiring significant lifting capacity and projection. Presented in a **1.0 ml prefilled syringe**, it contains a **high concentration (25 mg/ml) of cross-linked HA**, resulting in a robust, elastic gel optimized for durability and lifting power in the subcutaneous and supraperiosteal layers. While lidocaine isn’t integrated like in some competitors, adjunctive anesthesia (topical, local block, or nerve block) is essential for patient comfort during injection.https://skin-reboot.com/

**Core Technology & Properties:**
* **Monophasic NASHA Gel:** Features a homogeneous, non-animal stabilized HA matrix cross-linked with BDDE for biocompatibility and longevity. The monophasic structure ensures smooth flow and tissue integration.
* **Very High G-Prime (Elasticity):** Exhibits **exceptional resistance to deformation and high lifting force**, making it ideal for creating projection and supporting heavy tissues against gravity. Significantly firmer than medium-density fillers.
* **High Cohesivity:** Particles bind tightly together, providing excellent structural integrity, minimizing migration risk, and forming stable volumizing boluses.
* **High Viscosity:** Requires moderate injection force. Best suited for bolus placement or cautious fanning via cannula; less ideal for fine threading.
* **Optimized Particle Size:** Larger particle size compared to lighter fillers enhances durability in deep tissue planes.

**Mechanism of Action:**
1. **Volumetric Restoration:** Replaces lost volume in areas of profound deficit upon injection.
2. **Structural Lifting & Support:** Provides a stable scaffold to lift sagging tissues (e.g., midface, jawline) and restore skeletal contours.
3. **Fold Effacement:** Physically pushes up and fills very deep folds and creases.
4. **Hydration & Biostimulation:** HA binds water and provides a matrix for potential collagen stimulation over time.

**Primary Indications:**
* **Profound Midface Volume Loss & Cheek Augmentation:** Restoring significant malar volume and projection (supraperiosteal placement).
* **Deep Nasolabial Folds (NLFs) & Marionette Lines:** Correcting severe folds requiring substantial lifting capacity.
* **Chin Augmentation (Significant Projection):** Enhancing chin definition and forward projection.
* **Jawline Contouring & Pre-jowl Sulcus Correction:** Defining the mandibular angle and smoothing deep pre-jowl depressions.
* **Temporal Hollowing (Severe):** Restoring significant volume deficit in the temples (deep supraperiosteal).
* **Facial Asymmetry Correction (Structural):** Addressing significant volume discrepancies.

**Key Administration Considerations:**
* **Ready-to-Use:** No reconstitution required. Prime syringe carefully.
* **Anesthesia:** **Crucial:** Requires adjunctive anesthesia (topical cream + nerve block/local infiltration) due to high viscosity and deep placement. No integrated anesthetic.
* **Technique:** Primarily suited for **bolus deposition and cautious fanning**:
* **Needles:** Can be used with sharp needles (e.g., 25G+) for precise supraperiosteal placement (higher vascular risk).
* **Cannulas:** **Highly recommended** (e.g., 22-25G blunt cannulas, 38-50mm length) for safer placement in deep, vascular planes (NLFs, chin, jawline).
* **Depth:** **Deep subcutaneous tissue or supraperiosteal plane.** *Avoid superficial placement.*
* **Volume:** Moderate-to-large boluses. Gradual layering is essential. Avoid superficial overcorrection.
* **Post-Treatment:** Significant swelling, tenderness, and potential bruising are common. Avoid pressure/massage.
* **Longevity:** Results typically last **12-18 months or longer**, reflecting its high HA concentration, robust cross-linking, and deep placement.
* **Safety:** **High-risk product due to deep placement and high lifting force. Critical Risks:** **Vascular Occlusion/Compression & Embolism** (potentially severe). Requires **expert anatomical knowledge**, aspiration (if needle), cannula preference, small bolus volumes, and constant vigilance. Risk of visible nodules/lumps if placed too superficially or overfilled. Tyndall effect unlikely due to depth. Granuloma risk (rare).
* **Regulatory Status:** **CE marked** (Europe/international). **Not FDA-approved in the USA.**
* **Prescription:** Prescription medical device.

Ouye Deep Plus is a powerful tool for experienced injectors seeking to correct severe volume loss and restore structural support using a high-G’, durable monophasic HA gel, demanding meticulous technique and comprehensive anesthesia management.CONTACT US